Bioatla (BCAB) Q3 2024 earnings summary

Executive summary

• Advanced clinical programs with positive data in ADC and CTLA-4 antibody candidates, including head and neck cancer, melanoma, and non-small cell lung cancer, with two registrational trials planned for 2025.

• Net loss for Q3 2024 was $10.6 million, a significant improvement from $33.3 million in Q3 2023, driven by lower R&D and G&A expenses and $11.0 million in licensing revenue.

• Out-licensed CAB-Nectin-4 bispecific T-cell engager, generating $11.0 million upfront and eligibility for up to $133.5 million in milestones, extending cash runway into early 2026.

• Ongoing discussions for strategic collaboration on Phase 2 assets, with guidance for a near-term deal.

• As of September 30, 2024, cash and cash equivalents totaled $56.5 million, expected to fund operations into early 2026.

Financial highlights

• Q3 2024 research and development expenses were $16.4 million, down from $28.4 million in Q3 2023, due to program prioritization and trial completions.

• General and administrative expenses decreased to $5.9 million from $6.6 million year-over-year, mainly due to lower stock-based compensation.

• Recognized $11.0 million in collaboration revenue from a license agreement; no product sales in Q3 2024.

• Net cash used in operating activities for the nine months ended September 30, 2024, was $55.2 million, down from $74.1 million year-over-year.

• Cash and cash equivalents were $56.5 million as of September 30, 2024, with no debt outstanding.

Outlook and guidance

• Current cash is expected to fund operations into early 2026, supporting dose optimization and advancement of CAB-ROR2 and CAB-CTLA-4 to registrational trials.

• Anticipates initiating pivotal trials for ROR2 and CTLA-4 programs in 2025, with ROR2 ahead in timing.

• Guidance for a near-term strategic collaboration on at least one Phase 2 asset remains unchanged.

• R&D expenses are expected to decrease as certain clinical trials complete enrollment, but may rise again with new trial initiations.

• Additional capital will be needed for long-term development and commercialization.